Bio-byblos is a Taiwanese company devoted to the manufacturing of scaffolds and 3D cell culture substrates. Bio-byblos matrices provide a more realistic cell culture environment that allow the interaction between cells.
These scaffolds can be used for the study of the cell metabolism, the investigation of new drugs and the observation of cell behaviour in a growth enviroment similar to the in-vivo conditions. Medical research, drug testing and tissue culture are potential applications of these scaffolds.
The new TC-3 Bioreactor has been designed as a simple easy-to-use system suitable for cell culture under mechanical loading profiles defined by the user. It has been designed and manufactured thinking of the needs of researcher working on cell culture under mechanical stimuli.
The TC-3 combines the features of a traditional testing machine with the particular demands of cell culture, with special emphasis on the parts sterilization, easy assembling, sample inspection by microscopy techniques and easy manipulation. Also versatility and scalability is a key feature of hte TC-3 in which three grips models can be interchanged in order to adapt to the features of the testing substrate or scaffold.
The TEB1000 Master Unit provides the necessary conditions for cell growing that allow developing cell cultures under accurately controlled flow conditions. The most important advantages of dynamic culture over static culture are the following:
EBERS bioreactors are fully compatible with any other equipment and do not require any additional device to develop the cultures, with the exception of the culture chamber.
Use our vascular chamber to grow cell on tube-shaped scaffolds and the NEW P3D chambers to seed and culture cells on porous scaffolds under perfusion conditions, the simplest way to grow cells on porous scaffolds.
Cornelia Kasper studied Chemistry at the University Hannover and received her Diploma degree 1994. She performed her phD thesis at the Institute for Technical Chemistry 1995-1998 on: “Purification of proteins and other biological active compounds using novel chromatographic approaches”.
She was employed as EU liason officer at the University of Hannover 1998-2000. Afterwards she received a Habilitation-fellowship from the University of Hannover 2000-2006. She finished her Habilitation on “New approaches in cell culture techniques”and received the Venia legendi “Technische Chemie” in 2007.
2000-2011 Cornelia Kasper has been head of Cell Culture and Tissue Engineering Group at the Institute for Technical Chemistry, Leibniz University of Hannover. Furthermore she was head of young researcher group JRG “Large Scale Cultivation” within Cluster of Excellence “Rebirth” (from Regenerative Biology and Reconstructive Therapies).
Since October 2011 Cornelia Kasper has been appointed as full University Professor “Biopharmaceutical Technology and Products” at the Department of Biotechnology at Boku.
Application of cell culture technology for “biological testing” using cell based assays (e.g. biological active compounds, nanoparticles)
Study of effects of hydrodynamic forces and mechanotransduction
We are very happy to inaugurate our "Interviews with the experts" section with Dr. Kasper, one of the most reputated researchers in TE in Europe. Currently, she is focusing her research in three different lines involving cell culture and holds a the "Biopharmaceutical Technology and Products" full professorship at the University of Boku (Austria).
A resumed version of Dr. Kasper's CV is available here.
One of the major problems was to find suitable inter and transdisciplinary partners/team willing to really work together. Furthermore it was challenging to find a common "language" since the communication in the different research areas and between basic scientists and clinicians for examples differs quite a lot.
Visit conferences and meetings to gain insight into current research activities and try to get in contact with active researchers. Try to use the special acitivities often offered to suuport young researchers (e.g. SYIS at Termis meeting, summer/winter schools, workshops/trainings)
Funding is always a bottleneck. But I also think one reason for not having numerous tissue engineering products on market is the lack of understanding and/or harmonization of regulatory issues. Although ATMP guidelines were believed to solve the problems. I think and often see that research is focussed on different areas, technologies are quite advanced, coordination of the activities is often based on EU projects/networks and several developments are close to application/product. The translation of the research results and outcome of clinical studies into market and products is still inhibited by very complex and costly procedures.
I estimate that TE products could be applied within the next 5-8 years. Again, cost reimbursement remains one major issue when it comes to application of TE products in a broader basis. But TE products are much more complex in production and just no therapeutics like Asperin.
I personally do not believe that pioneers of TE will receive the nobel prize within the next decade.